HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutr

Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst con

NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “

Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shares shot up 4.8% during mid-day trading on Mo

Traws Pharma, Inc. $139,185,641.25 Common StockPreferred StockDebt SecuritiesWarrantsUnits This pros

The updated data package is expected to be resubmitted to MHRA during the third quarter of 2026. &#3

Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenz

Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing

HC Wainwright & Co. analyst Brandon Folkes downgrades Traws Pharma (NASDAQ:TRAW) from Buy to

Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory c

Traws Pharma shares fell after UK regulators deferred a planned influenza challenge study for tivoxa

Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining i

Tower Semiconductor (TSEM) jumped 4.7% in pre-market trading after announcing a multi-year supply ag

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a cl

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Traws Pharma, Inc. (NASDAQ:TRAW), a clinical-stage biopharmaceutical company developing novel therap

Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing

HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Buy a

Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.53) per share which beat the analyst con

Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based war

Hantavirus outbreak on a cruise ship sparks alarm as Schumer blames CDC cuts, warning weakened disea

Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as

Traws Pharma shares jump after the company advanced hantavirus antiviral candidates amid global moni

Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"),

NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “T

Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated

Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript

Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.71) per share which missed the analyst c

Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylacti

Entry into a Material Definitive Agreement PIPE Securities Purchase Agreement On April 15, 2026, Tra

Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shot up 8.8% on Monday. The stock traded as high

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with f

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with few

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for th

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for th

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mi

The study was designed as an active-controlled comparator trial versus PAXLOVID™ (nirmatrelvir/riton